文献速递老年慢病共病管理安宁疗护

停用与他汀类药物继续使用:一项系统综述

Discontinuation versus continuation of statins: A systematic review.
PubMed 文献 · J Am Geriatr Soc · 2024-07-25

该系统综述纳入36项研究(35项非随机研究,n=1,708,684;1项RCT,n=381),比较停用与他汀继续使用对全因死亡、心血管死亡、心血管事件及生活质量的影响。唯一RCT在预期寿命<1年人群中显示60天死亡率可能无差异;非随机研究一致提示停用他汀可能与死亡、心血管死亡及心血管事件风险相对增加相关,但证据确定性低。

要点

  • 在预期寿命<1年人群中,停用他汀与继续使用相比60天死亡率可能无差异(RCT)。
  • 非随机研究一致提示停用他汀可能与全因死亡、心血管死亡及心血管事件风险相对增加相关。
  • 非随机研究存在方法学局限,证据确定性高不确定性,需谨慎解读。

核心结论

  • 基于一项RCT,在预期寿命<1年人群中停用他汀似不影响短期死亡率。
  • 在该人群之外,非随机研究一致提示停用他汀可能与更差结局相关,但此结论不确定。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和Cochrane Central Registry(建库至2023年8月)。
  • 纳入≥18岁人群的RCT、队列研究、病例对照研究和准随机研究。
  • 共纳入36项研究(35项非随机研究,n=1,708,684;1项RCT,n=381)。
  • 采用叙述性总结,对部分研究进行meta分析,并使用GRADE评估证据确定性。

主要发现

  • 唯一RCT在预期寿命<1年人群中显示停用他汀与继续使用相比60天死亡率风险差为3.5%(90% CI -3.5至10.5)。
  • 非随机研究提示停用他汀与全因死亡风险相对增加相关(HR 1.92,95% CI 1.52至2.44,9项研究)。
  • 非随机研究提示停用他汀与心血管死亡风险相对增加相关(HR 1.63,95% CI 1.27至2.10,5篇报告)。
  • 非随机研究提示停用他汀与心血管事件风险相对增加相关(HR 1.31,95% CI 1.23至1.39,8篇报告)。
  • ≥75岁人群中的发现与主要结果一致。

临床怎么用

  • 对于预期寿命<1年的患者,停用他汀可能不影响短期死亡率,可结合个体情况决策。
  • 对于其他人群,停用他汀可能与更差结局相关,但证据不确定性高,应谨慎权衡利弊。

局限性

  • 非随机研究存在方法学局限,导致 findings 高度不确定。
  • 仅一项RCT且限于预期寿命<1年人群,证据适用范围有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinicians and patients often face a decision to continue or discontinue statins. We examined the impact of discontinuation of statins compared with continuation on clinical outcomes (all-cause mortality, cardiovascular [CV] mortality, CV events, and quality of life). METHODS: We conducted a systematic review. Randomized controlled trials (RCTs), cohort studies, case-control studies, and quasi-randomized studies among people ≥18 years were eligible. We searched MEDLINE, Embase, and Cochrane Central Registry (inception to August 2023). Two independent reviewers performed screening and extracted data. Quality assessment was performed by one author and verified by another. We summarized results narratively, performed meta-analysis for a subset of studies, and used GRADE to assess certainty of evidence. We summarized findings in the subgroup of persons ≥75 years. RESULTS: We retrieved 8369 titles/abstracts; 37 reports from 36 studies were eligible. This comprised 35 non-randomized studies (n = 1,708,684) and 1 RCT (n = 381). The 1 RCT was conducted among persons with life expectancy <1 year and showed there is probably no difference in 60-day mortality (risk difference = 3.5%, 90% CI -3.5 to 10.5) for statin discontinuation compared with continuation. Non-randomized studies varied in terms of population and setting, but consistently suggested that statin discontinuation might be associated with a relative increased risk of mortality (hazard ratio (HR) 1.92, 95% CI 1.52 to 2.44, nine studies), CV mortality (HR 1.63, 95% CI 1.27 to 2.10, five reports), and CV events (HR 1.31, 95% CI 1.23 to 1.39, eight reports). Findings in people ≥75 years were consistent with main results. There was a high degree of uncertainty in findings from non-randomized studies due to methodological limitations. CONCLUSIONS: Statin discontinuation does not appear to affect short-term mortality near end-of-life based on one RCT. Outside of this population, findings from non-randomized studies consistently suggested statin discontinuation may be associated with worse outcomes, though this is uncertain.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Peixoto C, Choudhri Y, Francoeur S, et al. Discontinuation versus continuation of statins: A systematic review. J Am Geriatr Soc. 2024. PMID: 39051828. doi:10.1111/jgs.19093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。